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Experimental infection of pigs with the newly identified swine hepatitis E
virus (swine HEV), but not with human strains of HEV
Abstract
A novel virus of pigs, swine hepatitis E virus (swine HEV), was recently identified and shown to be
antigenically and genetically related to human HEV. In the present study, we attempted to infect specific-
pathogen-free (SPF) pigs experimentally with swine HEV or with human strains of HEV. Serum samples
collected from naturally infected pigs were used as the source of swine HEV. Pigs inoculated intravenously
with serum samples containing swine HEV seroconverted to anti-HEV 4 to 8 weeks postinoculation, and the
virus spread to an uninoculated pig. Swine HEV was detected in nasal and rectal swab materials as early as 2
weeks postinoculation and for 4 to 8 weeks thereafter. Viremia appeared 4 to 6 weeks postinoculation and
lasted 1 to 3 weeks. The inoculated pigs appeared clinically normal and serum liver enzymes were not
significantly elevated. In contrast, pigs were not infected when inoculated intravenously with about 105
monkey infectious doses of one of two human strains of HEV (Sar-55 or Mex-14).
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Summary. A novel virus of pigs, swine hepatitis E virus (swine HEV), was re-
cently identified and shown to be antigenically and genetically related to human
HEV. In the present study, we attempted to infect specific-pathogen-free (SPF)
pigs experimentally with swine HEV or with human strains of HEV. Serum sam-
ples collected from naturally infected pigs were used as the source of swine HEV.
Pigs inoculated intravenously with serum samples containing swine HEV sero-
converted to anti-HEV 4 to 8 weeks postinoculation, and the virus spread to an
uninoculated pig. Swine HEV was detected in nasal and rectal swab materials
as early as 2 weeks postinoculation and for 4 to 8 weeks thereafter. Viremia
appeared 4 to 6 weeks postinoculation and lasted 1 to 3 weeks. The inoculated
pigs appeared clinically normal and serum liver enzymes were not significantly
elevated. In contrast, pigs were not infected when inoculated intravenously with
about 105 monkey infectious doses of one of two human strains of HEV (Sar-55
or Mex-14).

Hepatitis E virus (HEV), one of the causative agents of enterically transmitted
non-A, non-B hepatitis, is currently classified in the family Caliciviridae [15, 24],
although this classification has been questioned [18]. HEV is a single-stranded
RNA virus without an envelope [24, 27, 28]. The positive sense viral genome of
about 7.5 kb contains 3 open reading frames (ORFs). ORF1 probably encodes
viral nonstructural proteins, ORF 2 the putative capsid protein and ORF3 a protein
of unknown function [5, 22, 24, 27, 28].
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The apparent primary source of infection for hepatitis E is human feces from
infected individuals [1, 4, 24, 26, 36]. Antibodies to HEV (anti-HEV) have been
found in many countries around the world, both in endemic and non-endemic
areas, but hepatitis E has been largely confined to endemic areas comprising
developing countries [1, 2, 6, 8–9, 10, 12, 16, 20, 23, 25, 26, 29, 30, 36, 38].
The disease is usually not fatal, although a high mortality rate, up to 20%, has
been reported for infected pregnant women [11, 14, 24]. Hepatitis E has been suc-
cessfully transmitted to various species of non-human primates [31, 32, 34, 35].
It has also been reported that domestic pigs, lambs and laboratory rats could be
experimentally infected with a human strain of HEV [3, 19, 37]. Since naturally-
acquired HEV antibodies have been detected in primates, rodents, and swine,
it has been suggested that hepatitis E might be a zoonotic disease [7, 17,
19, 33].
Recently, we identified and characterized the first animal strain of HEV, swine
HEV [21]. Swine HEV is a ubiquitous agent in pigs in the midwestern United
States and antibodies to it cross-react with capsid antigen from strains of human
HEV. The putative capsid gene (ORF2) of swine HEV shares about 79 to 80%
sequence identity at the nucleotide level and 90 to 92% identity at the amino
acid level with that of human HEV strains. The antigenic and genetic similarities
between swine and human HEV suggested that the two viruses belong to the same
family, and that swine HEV infection of pigs might serve as an alternative animal
model for study of human HEV [21].
In the present study, we attempted to infect specific-pathogen-free (SPF) pigs
with the swine HEV, and with two divergent strains of human HEV. Serum samples
collected from naturally infected pigs during the acute phase of infection [21] were
used as the source of swine HEV. The titer of viral genomes in the serum samples
was determined by a nested-PCR with primers specific for swine HEV (see below).
One genome equivalent (GE) is defined as the number of HEV genomes present
in the highest serial dilution positive by RT-PCR. At least one serum sample from
each of the four naturally-infected piglets contained detectable levels of swine
HEV RNA (Table 1). The amount of virus in the inocula, however, was relatively
low: 103 GE/ml of serum for piglets #4 and #14, <102 GE/ml for piglets #7 and
#15. Therefore, we chose to infect pigs by the intravenous route because this
route has required less virus to initiate an infection compared to the oral route in
previous studies of human HEV [34].
Seven crossbred (Yorkshire, Hampshire, and Spotted Poland China) 4 week-
old SPF pigs were randomly divided into 2 groups of 5 and 2 each (Groups A
and B). Each group of pigs was housed in a separate room in a BL-2 facility
and maintained under conditions that met all relevant requirements. Pig-to-pig
contacts were allowed within the same room. Serum samples collected from four
piglets in a prospective study [21] were used for inoculation of four SPF pigs in
group A (Table 1). Two hundred ml each of 4 serial weekly samples of serum
collected from one piglet were inoculated, in chronological order, via a pediatric
catheter into the ear vein of an SPF pig (Table 1). The needle and catheter were
flushed with PBS buffer between each injection. The fifth pig in group A was
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Table 1. Experimental infection of specific-pathogen-free pigs with swine hepatitis E virus
HEV markers in HEV markers in recipient pigs
inocula (wk)a Recipient (wks PIb)
3 2 1 0 Pig ID 0 1 2 3 4 5 6 7 8 9 10
Serum Group A
Piglet #7 A1
Anti-HEV − − − C − − − − − − − − C C C
Serum viral RNA + n/a C − − − − − − − C C C − −
Fecal viral RNA − − − C C C C C C C C
Nasal viral RNA − − − C C − C C − − −
Piglet #14 A2
Anti-HEV − − − C − − − − C C C C C C C
Serum viral RNA − C C C − − − − C − − − − − −
Fecal viral RNA − − − C C − C C − − −
Nasal viral RNA − − − − C − C C C − −
Piglet #15 A3
Anti-HEV − − − c − − − − − − − − C C C
Serum viral RNA − − C C − − − − − − C C − − −
Fecal viral RNA − − C − C C C C C − −
Nasal viral RNA − − − C C − C C C − −
Piglet #4 A4
Anti-HEV − − − C − − − − − − − − C C C
Serum viral RNA − − C − − − − − − − C C − − −
Fecal viral RNA − − − − − − C C C − −
Nasal viral RNA − − − C C − C C − − −
uninoculated A5
Anti-HEV − − − − − − − − C C C
Serum viral RNA − − − − − − C C − − −
Fecal viral RNA − − − − C C C C C C −
Nasal viral RNA − − − − C − C C − − −
PBS buffer Group B
Anti-HEV B1 − − − − − − − − − − −
Anti-HEV B2 − − − − − − − − − − −
a Group A: 200 ml each of weekly serum samples collected from naturally infected piglets
(#4, 7, 14, 15) for 3 weeks (3, 2, 1) prior to and the week of (0) seroconversion or 2 days (0)
before necropsy (piglet # 15) were inoculated, in chronological order, into the ear vein. n/a:
not available. Group B: inoculated with PBS buffer via I.V. or oronasal route
bwks PI Weeks postinoculation
cThe OD value was rising, but was still below the ELISA cutoff ()
not inoculated. One SPF pig in group B was inoculated with 1 ml of PBS buffer
intravenously and another with 4.5 ml of PBS buffer oronasally.
Clinical samples (serum, nasal swab and rectal swab) were collected before
inoculation and weekly thereafter for 10 weeks. Nasal and rectal swab samples
were collected with the Cellmatics viral transport system (DIFCO Laboratories,
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Detroit, MI). For nasal swab collection, the external nares were wiped with a ster-
ile towel prior to inserting the swab 1–2 inches into the nasal cavity. An ELISA
for anti-HEV in swine was standardized as previously described [21]. An HPLC-
purified 55 kD truncated form of the putative capsid protein, expressed from a
recombinant baculovirus containing ORF2 of a human strain of HEV (Sar-55)
was used as antigen for the ELISA [33]. Sera taken from the experimentally-
inoculated pigs were tested in duplicate for IgG and IgM anti-HEV. Serum levels
of the liver enzymes alkaline phosphatase (AP), alanine aminotransferase (ALT),
gamma glutamyltransferase (GGT), and sorbitol dehydrogenase (SDH) were as-
sayed weekly by standard methods at Iowa State University Veterinary Clinical
Pathology Laboratory.
For detection of swine HEV by RT-PCR, total RNA was extracted with
TriZol reagent (GIBCO-BRL, Gaithersburg, MD) from 100ml of nasal or
rectal swab material or serum. Total RNA was reverse transcribed with a swine
HEV-specific primer and SuperScript II reverse transcriptase (GIBCO-BRL,
Gaithersburg, MD) at 42 C for 1 h; cDNA was amplified by PCR using
AmpliTaq Gold polymerase (Perkin Elmer, Norwalk, CT). A nested RT-PCR
was used to detect low levels of virus and to confirm first round positives. The
PCR reaction consisted of 39 cycles of denaturation at 94 C for 1 min, annealing
at 52 C for 1 min, and extension at 72 C for 1.5 min, followed by a nested-
PCR of 39 cycles using 10 ml of the first round PCR product. First round:
forward primer, 50-AGCTCCTGTACCTGATGTTGACTC-30, reverse primer,
50-CTACAGAGCGCCAGCCTTGATTGC-30; second round: forward primer,
50-GCTCACGTCATCTGTCGCTGCTGG-30, reverse primer, 50-GGGCTGAA-
CCAAAATCCTGACATC-30. Reagent preparation, RNA extraction, cDNA syn-
thesis and PCR assembly were all performed in a laboratory separate from the one
in which the PCR products were analyzed in order to avoid cross-contamination.
The swine HEV-infected pigs appeared clinically normal, and jaundice was
not observed. Serum levels of liver enzymes remained normal, in contrast to what
is often seen in primates infected with human strains of HEV [31, 32, 34]. Anti-
HEV was detected in all four pigs inoculated with the serum samples as well
as in the uninoculated control pig housed in the same room (group A, Table 1).
The first pig seroconverted to IgG anti-HEV 4 weeks postinoculation and the four
others seroconverted 4 weeks later (Table 1). IgM anti-HEV appeared earlier than
IgG anti-HEV, but lasted only 1 to 2 weeks whereas the IgG anti-HEV was still
present at the end of the 10 week experiment (Fig. 1). Pigs inoculated with PBS
buffer (group B) remained seronegative throughout the experiment, and were not
further tested (Table 1).
The weekly serum samples as well as the nasal and rectal swab samples from
group A pigs were tested for viral RNA by RT-PCR with primers specific for
swine HEV (Table 1). PCR fragments amplified from serum, nasal and rectal
samples of two inoculated pigs were cut from 1% agarose gels and purified by
the glassmilk procedure with a Geneclean Kit (Bio101, La Ja Jolla, CA). The
purified PCR fragments were sequenced (both strands) with an Automated DNA
Sequencer using swine HEV-specific primers and confirmed to represent swine
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Fig. 1. Swine HEV infection in experimentally inoculated SPF pigs (A1, A2, A3 and A4)
and in an uninoculated contact control SPF pig (A5). IgG and IgM HEV antibodies are
plotted as ELISA OD values. Presence (dD detected by first round PCR; D detected only
by a nested PCR) or absence ( ) of swine HEV RNA in serum, fecal and nasal samples is
indicated
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HEV sequences (data not shown). Viremia of 1 to 3 weeks’ duration was detected
in all four inoculated pigs and in the sham-inoculated control about 4 to 6 weeks
postinoculation. The disappearance of viremia was temporally related to the
appearance of anti-HEV (Table 1, Fig. 1). Swine HEV RNA was also found
in rectal and nasal swab samples as early as 2 weeks postinoculation and per-
sisted, even after viremia had disappeared, for up to 7 weeks (Table 1, Fig. 1).
Fecal virus shedding appeared to increase for a 2 to 3 week period, usually at 5 to
7 weeks postinoculation (data not shown). In the sham-inoculated contact control
pig (A5, Table 1), swine HEV was detected in the rectal and nasal swab samples
about 2 weeks after the virus first appeared in the feces of an inoculated pig (A3,
Table 1).
Viremia was detected variably from 4 to 6 weeks postinoculation in infected
pigs. In contrast, viremia appeared as early as 9 days postinoculation in primates
infected intravenously with human strains of HEV [31]. The difference may sim-
ply reflect a dose-dependent effect since the amount of swine HEV in the inocula
was relatively low, and in primates infected with human strains of HEV [31,
32, 35], the time of virus appearance was related to dose. IgG anti-HEV was
first detected up to one week after viremia ceased, and remained positive there-
after. Unlike human HEV infections in primates [31, 33, 35], elevation of serum
liver enzymes, indicative of liver injury, was not associated with either viremia
or seroconversion. The experimentally infected pigs remained clinically normal
as had the naturally infected pigs in our prospective study [21]. However, dose
dependence of clinical response to human HEV has also been documented [34].
Biochemical evidence of hepatitis was prominent in primates inoculated with
higher concentrations of human HEV, but was absent in infected animals given
a low dose of virus [34]. Therefore, further experiments are warranted to study
whether swine HEV is pathogenic for pigs when a higher concentration of virus
is administrated.
Previously, we found that swine HEV is highly contagious under natural
conditions [21]. In the present study, the uninoculated control pig in group A
quickly became infected, almost certainly through contact with the inoculated
animals housed in the same room. The incubation period to fecal excretion of
virus for the sham-inoculated control pig appeared to be 1 to 2 weeks. The rapid
spread of the virus to the control pig means that only the first pig (A3) to be
infected (Table 1) could be confirmed as an experimental inoculation. The other
3 inoculated pigs could have had a 3 week incubation period for the inoculated
virus or a one week incubation period for a contact virus.
Human strains of HEV are normally transmitted by the fecal-oral route.
Therefore, it was a surprise to detect swine HEV in nasal swab materials since
that usually is indicative of viral transmission via a respiratory route. It is pos-
sible that the nasal swab samples were contaminated with a small amount of blood
resulting from trauma to the nasal cavity during swabbing; however, swine HEV
RNA appeared about 2 to 3 weeks earlier in the nasal swab samples than in the
serum in 4 of the 5 pigs (Table 1), suggesting that this explanation was unlikely.
More likely, the pigs’ snouts may have been contaminated by fecal materials.
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Clearly, the significance of swine HEV in the nasal swab materials needs to be
further evaluated.
For inoculation of SPF pigs with human strains of HEV, stool suspensions
containing human strains of HEV, Sar-55 [31] and Mex-14 [13], were used as
the inocula. The infectivity titer of both strains was determined in primates ([34],
Purcell et al., unpubl. data). The titer of viral genomes in inocula was also de-
termined with a nested-PCR by using strain-specific primers as described be-
low. The amount of virus in the inocula was about 105 monkey infectious doses
(MID), which corresponded to 107 GE/ml for Mex-14, and 106 GE/ml for Sar-55.
Three-week-old crossbred pigs from the same SPF herd used for the swine HEV
inoculations were randomly divided into 3 groups of 3 pigs each. Each group
was housed in a separate room in a BL-3 facility. One group was inoculated
with HEV, strain Sar-55, and another group with HEV, strain Mex-14. Each pig
received an intravenous injection of 0.5 ml of inoculum containing about 105
MID of HEV. The third group was inoculated with PBS buffer. The animals were
monitored weekly for 14 weeks for evidence of hepatitis. Preinoculation values
for anti-HEV and baseline serum levels of the liver enzymes were determined. A
collection tray was used to gather feces.
For detection of human strains of HEV, feces were resuspended in 10% (w/v)
MgCC/CaCC-free PBS buffer, and clarified by low-speed centrifugation. RNAs
from 100 ml of 10% fecal samples or 100 ml of sera were extracted with TriZol
reagent. As a positive control, ten ml of stool suspension containing about 10
genome equivalents of HEV Sar-55 was mixed with 100 ml of 10% pig fecal
suspension or 100 ml of serum. Superscript II reverse transcriptase was used
as described by the manufacturer. The PCR reaction consisted of 40 cycles of
denaturation at 94 C for 1 min, annealing at 56 C for 1 min, and extension at
72 C for 1.5 min, followed by a nested-PCR of 40 cycles using 10 ml of the
first round PCR product. The PCR primers were strain-specific and based on
published sequences. PCR primers for the Sar-55 strain [31] were: first round,
forward primer, position 4 184–4 205 and reverse primer, position 4 534–4 555;
second round, forward primer, position 4 251–4 270 and reverse primer, position
4 521–4 540. PCR primers for the Mex-14 strain [13] were: first round, forward
primer, position 4 437–4 460 and reverse primer, position 4 866–4 889; second
round, forward primer, position 4 484–4 505 and reverse primer, position 4 812–
4 833.
Clinically, all pigs inoculated with the two human strains of HEV remained
normal throughout the entire experimental period, and jaundice was not observed
in any of the inoculated swine. We did not observe significant elevation of liver
enzymes tested (data not shown). We were unable to detect IgG anti-HEV by
ELISA in any samples collected from these experimentally-inoculated swine. A
nested RT-PCR was used in an attempt to amplify HEV RNA from the weekly
serum and fecal samples of the inoculated swine. The RT-PCR assay was sensitive
enough to amplify HEV product from a positive control containing about 10 viral
genome equivalents. However, HEV RNA was not detected in either the serum
or fecal samples of the inoculated swine.
1412 X.-J. Meng et al.
Balayan et al. reported that Russian domestic swine could be experimentally
infected with a Central Asian strain of HEV isolated from a naturally infected
patient [3]. The experimentally-induced hepatitis appeared to be quite severe
since the infected swine developed jaundice. In the present study, we examined
the susceptibility of crossbred SPF swine to experimental infection with high
doses of genetically divergent strains of human HEV from Asia (Sar-55) and
from Mexico (Mex-14). However, we were unable to infect SPF pigs with either
of these human strains although we inoculated 1000 to 10,000 times as much
human virus as we had the swine virus.
A possible explanation for our failure to infect SPF pigs with human strains of
HEV is that there is a difference in susceptibility of different swine breeds to HEV
infection. Crossbred SPF pigs were used in our experiment. However, crossbred
pigs have been widely used for virus transmission studies and have been shown to
be highly susceptible to many viruses. Alternatively, the transmissibility of various
human HEV strains may differ. Since the virus was not recovered from the pigs
reportedly infected in the previous study [3], it is not known if it more closely
resembled human HEV or swine HEV. It will now be very important to determine
whether swine HEV can infect humans. As a first step, we are attempting to infect
non-human primates with the swine virus.
In addition to swine, rodents and lambs are also reported to be susceptible to
infection with HEV [17, 19, 37]. However, little is known regarding infection of
these species with human strains of HEV, and the relative sensitivity to infection
of these animals compared to nonhuman primates needs to be evaluated. These
species should also be examined to determine if they have their own strains of
HEV.
Our previous prospective study of naturally infected pigs revealed that swine
HEV causes an asymptomatic infection in young pigs [21]. We have now ex-
perimentally reproduced this asymptomatic infection in SPF pigs, and recovered
swine HEV genomic sequence from them. Although swine HEV infection in pigs
was somewhat similar to human HEV infection in primates, differences in the
course of infection and in clinical and pathological manifestations were noted.
Nevertheless, swine HEV infection of pigs may be a useful alternative animal
model to study the natural history of HEV as well as the ecological, biological
and pathological differences between swine and human HEV. Studies of swine
HEV infection of pigs may also prove useful in developing an effective vaccine
for HEV infection in humans.
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